Capacity building to support the uptake of biosimilars in a multistakeholder approach
Biosimilar medicines have a similar efficacy and safety compared with their reference medicines and hold the potential to achieve significant savings for health systems and improve access to medicines for patients. The current deadline is 9 Feb 2024, 16:00 UTC.
What the buyer needs
- Biosimilar medicines have a similar efficacy and safety compared with their reference medicines and hold the potential to achieve significant savings for health systems and improve access to medicines for patients.
- Still, barriers remain and impede their successful entry into the market and uptake by health systems.
- This call for tenders aims to support national authorities in implementing policies and practices that improve biosimilar competition, as a means to contribute to the accessibility, affordability and availability of…
- It will do so by proposing a series of capacity-building activities, based on best-practices and recommendations drawn from an analysis of current national biosimilar policies and their impact on savings and access.
Procurement signals
- Procedure: HADEA/2023/OP/0040
- Procedure type: Source procedure code open
- Contract type: Services contract (31095498)
- Submission method: Electronic submission
- Published: 11 Dec 2023
Procurement categories
CPV labels are not yet mapped locally, so the official category codes are shown as source-backed identifiers.
Programme and geography
Derived from official EU Funding & Tenders portal source fields. Use this as a shortlisting aid; the official tender record remains authoritative.
Source-backed details
Original identifiers and classification fields from the EU tender source.
- HADEA/2023/OP/0040
- 38025fa2-ca41-4e49-a26d-4a4e48edca5a-CN
- Source procedure code open
- Services contract (31095498)
- Europe/Brussels
- 9 Feb 2024, 16:00 UTC
- 1 Jul 2026, 09:21 UTC
Full official description
Biosimilar medicines have a similar efficacy and safety compared with their reference medicines and hold the potential to achieve significant savings for health systems and improve access to medicines for patients. Still, barriers remain and impede their successful entry into the market and uptake by health systems. This call for tenders aims to support national authorities in implementing policies and practices that improve biosimilar competition, as a means to contribute to the accessibility, affordability and availability of medicines for patients in the EU. It will do so by proposing a series of capacity-building activities, based on best-practices and recommendations drawn from an analysis of current national biosimilar policies and their impact on savings and access.